Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
27.32
-1.13 (-3.97%)
At close: Sep 12, 2025, 4:00 PM EDT
27.52
+0.20 (0.73%)
After-hours: Sep 12, 2025, 4:00 PM EDT
Inhibrx Biosciences Employees
As of December 31, 2024, Inhibrx Biosciences had 161 total employees, including 156 full-time and 5 part-time employees. The number of employees decreased by 11 or -6.40% compared to the previous year.
Employees
161
Change (1Y)
-11
Growth (1Y)
-6.40%
Revenue / Employee
$8,696
Profits / Employee
-$1,016,733
Market Cap
398.64M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 161 | -11 | -6.40% |
| Dec 31, 2023 | 172 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
INBX News
- 4 weeks ago - Inhibrx Reports Second Quarter 2025 Financial Results - PRNewsWire
- 4 months ago - Inhibrx Reports First Quarter 2025 Financial Results - PRNewsWire
- 5 months ago - Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President - PRNewsWire
- 6 months ago - Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results - PRNewsWire
- 8 months ago - Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer - PRNewsWire
- 8 months ago - Inhibrx Biosciences Announces Loan Agreement with Oxford Finance - PRNewsWire
- 10 months ago - Inhibrx Biosciences Reports Third Quarter 2024 Financial Results - PRNewsWire
- 11 months ago - Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform - Seeking Alpha